30 September 2026
30 September 2026
The initiative is designed to help post-seed health science enterprises secure investment, form corporate partnerships.
Orforglipron shows modestly greater weight and HbA1c reductions than oral semaglutide, supporting its potential in type 2 diabetes.
The agreement grants Knight Therapeutics rights to market the medicine for mycosis fungoides and Sézary syndrome subtypes.
Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.
This bet comes amid the strong industry buzz around the approval of Revolution Medicines’ OS-doubling pancreatic cancer treatment, Rasonque.
AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
